Abstract
The mainstay of treatment for adults with soft-tissue sarcomas is wide surgical excision. Half of all patients with adequate local control of high-grade sarcomas develop distant metastases and, despite additional treatment, ultimately die from their disease. This daunting reality has resulted in a three-decade research effort to assess the efficacy of adjuvant therapy for adult soft-tissue sarcomas. The multitude of histopathological subtypes, each with its own biology and clinical behavior, and the rarity of adult soft-tissue sarcomas as a whole greatly complicate such an assessment. This Perspectives article examines data that support or refute the use of adjuvant chemotherapy in the treatment of soft-tissue sarcomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Omura, G. A. et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J. Clin. Oncol. 3, 1240–1245 (1985).
Antman, K. et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J. Clin. Oncol. 2, 601–608 (1984).
Elias, A. D. & Antman, K. H. Adjuvant chemotherapy for soft-tissue sarcoma: a critical appraisal. Semin. Surg. Oncol. 4, 59–65 (1988).
Elias, A. D. & Antman, K. H. Adjuvant chemotherapy for soft tissue sarcoma: an approach in search of an effective regimen. Semin. Oncol. 16, 305–311 (1989).
Mertens, W. C. & Bramwell, V. H. Adjuvant chemotherapy in the treatment of soft-tissue sarcoma. Clin. Orthop. Relat. Res. 289, 81–93 (1993).
Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst. Rev. Issue 4 Art. No. CD001419. doi:10.1002/14651858.CD001419 (2000).
Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350, 1647–1654 (1997).
Verweij, J. & Seynaeve, C. The reason for confining the use of adjuvant chemotherapy in soft tissue sarcoma to the investigational setting. Semin. Radiat. Oncol. 9, 352–359 (1999).
Antman, K. H. Adjuvant therapy of sarcomas of soft tissue. Semin. Oncol. 24, 556–560 (1997).
Judson, I. Adjuvant chemotherapy of soft tissue sarcoma-current status. Sarcoma 4, 149–150 (2000).
Bramwell, V. H. Adjuvant chemotherapy for adult soft tissue sarcoma: Is there a standard of care? J. Clin. Oncol. 19, 1235–1237 (2001).
Figueredo, A. et al. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: a clinical practice guideline. Sarcoma 6, 5–18 (2002).
Casali, P. G. & Picci, P. Adjuvant chemotherapy for soft tissue sarcoma. Curr. Opin. Oncol. 17, 361–365 (2005).
Bramwell, V. H. Controversies in surgical oncology: routine anthracycline-based adjuvant chemotherapy for stage III extremity soft tissue sarcoma. Ann. Surg. Oncol. 14, 1254–1256 (2007).
Blay, J. Y. & Le Cesne, A. Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Oncologist 14, 1013–1020 (2009).
Schuetze, S. M. & Patel, S. Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? Oncologist 14, 1003–1012 (2009).
O'Sullivan, B. et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet 359, 2235–2241 (2002).
Yang, J. C. et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 16, 197–203 (1998).
Pisters, P. W., O'Sullivan, B., Maki, R. G. Evidence-based recommendations for local therapy for soft tissue sarcomas. J. Clin. Oncol. 25, 1003–1008 (2007).
Greene, F., Page, D. L., Fleming, I. D., Fritz, A. G., Balch, C. M., Haller DM, and Morrow M (eds). AJCC Cancer Staging Manual, Sixth Edition (Springer, New York, 2002).
Borden, E. C. et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 5, 840–850 (1987).
Mouridsen, H. T. et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer Clin. Oncol. 23, 1477–1483 (1987).
Gottlieb, J. A. et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat. Rep. 60, 199–203 (1976).
Fidias, P., Demetri, G. D. & Harmon, D. C. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/Dana-Farber/Partners CancerCare Study [abstract]. Proc. Am. Soc. Clin. Oncol. 17, a1977 (1998).
Patel, S. R. et al. Preliminary results of a two-arm phase 2 trial of gemcitabine in patients with gastroinstestinal leiomyosarcomas and other soft-tissue sarcomas (STS) [abstract]. Sarcoma 3, 56 (1999).
van Hoesel, Q. G. et al. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann. Oncol. 5, 539–542 (1994).
Edmonson, J. H. et al. Phase II study of docetaxel in advanced soft tissue sarcomas. Am. J. Clin. Oncol. 19, 574–576 (1996).
Verweij, J. et al. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J. Clin. Oncol. 18, 2081–2086 (2000).
Gian, V. G., Johnson, T. J., Marsh, R. W., Schuhmacher, C. & Lynch, J. W. A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J. Exp. Ther. Oncol. 1, 186–190 (1996).
Patel, S. R. et al. Phase II study of paclitaxel in patients with soft tissue sarcomas. Sarcoma 1, 95–97 (1997).
Loehrer, P. J. Sr. et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J. Clin. Oncol. 7, 1655–1659 (1989).
Edmonson, J. H. et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11, 1269–1275 (1993).
Santoro, A. et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537–1545 (1995).
Omura, G. A. et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52, 626–632 (1983).
Hensley, M. L. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 20, 2824–2831 (2002).
Maki, R. G. et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J. Clin. Oncol. 25, 2755–2763 (2007).
Brodowicz, T. et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma 4, 151–160 (2000).
Fakhrai, N. et al. Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. Wien. Klin. Wochenschr. 122, 614–619 (2010).
Petrioli, R. et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am. J. Clin. Oncol. 25, 468–473 (2002).
Frustaci, S. et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 19, 1238–1247 (2001).
Frustaci, S. et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65, 80–84 (2003).
O'Connor, J. M., Chacón, M., Petracci, F. E. & Chacón, R. D. Adjuvant chemotherapy in soft tissue sarcoma (STS): A meta-analysis of published data [abstract]. J. Clin. Oncol. 26 (15 Suppl.), a10526 (2008).
Woll, P. J. et al., Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J. Clin. Oncol. 25 (18 Suppl.), a10008 (2007).
Afonso, S. L., Ramos, L. A., Viani, G. A., Stefano, E. & Afonso, V. Improvement in the survival for adult soft tissue sarcoma with adjuvant anthracycline chemotherapy combination: a meta-analysis and metaregression [abstract]. J. Clin. Oncol. 28 (15 Suppl.), a10024 (2010).
Pervaiz, N. et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113, 573–581 (2008).
Gortzak, E. et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer 37, 1096–1103 (2001).
Fleming, T. R. Clinical trials: discerning hype from substance. Ann. Intern. Med. 153, 400–406 (2010).
Le Cesne, A. et al., The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]. J. Clin. Oncol. 26 (15 Suppl.), a10525 (2008).
Engstrom, P. F. et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J. Natl Compr. Canc. Netw. 7, 778–831 (2009).
Carlson, R. W. et al. Breast cancer. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 7, 122–192 (2009).
Montie, J. E. et al. Bladder cancer. Clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 3, 19–34 (2005).
Ychou, M. et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 20, 1964–1970 (2009).
Bramwell, V. H., Anderson, D. & Charette, M. L. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst. Rev., CD003293 (2003).
Wilson, R. E. et al. Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch. Surg. 121, 1354–1359 (1986).
Verschraegen, C. F. et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J. Clin. Oncol. 28 (15 Suppl.), a10004 (2010).
US National Library of Medicine. Clinicaltrials.gov [online]. (2010).
Casali, P. G., Jost, L., Sleijfer, S., Verweij, J. & Blay, J. Y. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20 (4 Suppl.), 132–136 (2009).
Demetri, G. D. et al. Soft tissue sarcoma. J. Natl Compr. Canc. Netw. 8, 630–674 (2010).
Gronchi, A. et al., Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS). J. Clin. Oncol. 28 (15 Suppl.), a10003 (2010).
Tierney, J. F., Mosseri, V., Stewart, L. A., Souhami, R. L. & Parmar, M. K. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br. J. Cancer 72, 469–475 (1995).
Author information
Authors and Affiliations
Contributions
Both authors researched the data for the article, provided substantial contributions to the discussion, contributed equally to the writing, review and editing of the manuscript before submission and in response to referee and editorial comments.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Matushansky, I., Taub, R. Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma. Nat Rev Clin Oncol 8, 434–438 (2011). https://doi.org/10.1038/nrclinonc.2011.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.36